Which ASX All Ords stock is up 15% on guidance upgrade?

Let's find out what is getting investors excited on Tuesday.

| More on:
Man drawing an upward line on a bar graph symbolising a rising share price.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ASX All Ordinaries index is having a strong session on Tuesday.

In morning trade, the widely followed index is up 1.1% to 8,786.2 points. This has been driven by news of a ceasefire between Israel and Iran.

One ASX All Ords stock that is delivering an even stronger gain for its shareholders is Cogstate Ltd (ASX: CGS).

At the time of writing, the neuroscience technology company's shares are up 15% to a 52-week high of $1.55.

What is Cogstate?

Before we tackle why its shares are rising strongly today, let's just look at what Cogstate actually does.

The ASX All Ords stock describes itself as a neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare.

Its technologies provide rapid, reliable and highly sensitive computerised cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture.

In addition, it notes that its clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting.

Why is this ASX All Ords stock jumping?

Investors have been fighting to get hold of the company's shares today this morning after it released an update on its guidance for FY 2025.

According to the release, the second half of FY 2025 has been stronger than expected. As a result, the company expects its revenue to be in the range of US$28.1 million to US$30.1 million in revenue and US$6.8 million to US$8.8 million in profit before tax.

This reflects a strong performance across the company's core business segments.

In light of the above, the ASX All Ords stock now expects its revenue to be between US$52 million and US$54 million in FY 2025. This represents a 20% to 24% increase over the previous year.

Profit before tax is forecasted to range from US$12 million to US$14 million, a significant improvement of 69% to 97% compared to FY 2024.

Following today's gain, this ASX All Ords stock is now up a sizeable 37% since this time last year. To put that into context, a $10,000 investment this time last year would now have turned into a sizeable $13,700.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cogstate. The Motley Fool Australia has positions in and has recommended Cogstate. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A female scientist sits at a microscope in a Universal Biosensors laboratory smiling while her colleague checks beakers of COVID-19 samples in the background.
Healthcare Shares

This probiotics company has just struck a distribution deal, sending its shares sharply higher

Shares in Biome Australia have jumped after the company announced a distribution deal for its probiotic products in Canada.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Massive capital raise to progress drug trials announced

This raise will set the company up for years.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

4DMedical shares jump again today. Here's what investors liked

Commercial momentum builds following a busy quarterly update.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

I think the market is wrong about CSL shares

When a world-class business loses tens of billions in value, I think it’s worth asking whether the market has overreacted.

Read more »

Ecstatic man giving a fist pump in an office hallway.
Healthcare Shares

Why is the ResMed share price jumping 7% today?

This sleep disorder treatment giant delivered another three months of strong growth.

Read more »

A young man goes over his finances and investment portfolio at home.
Healthcare Shares

Could Mesoblast shares hit $4.45 in 2026?

Bell Potter thinks this biotech could be cheap and heading much higher.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

This broker just upgraded this ASX healthcare stock and is predicting 30% upside

A new collaboration has sparked interest in this healthcare stock.

Read more »

A man sees some good news on his phone and gives a little cheer.
Healthcare Shares

Why this speculative ASX stock could rise 80%

Let's see what Bell Potter is saying about this small cap.

Read more »